17:47 , Jan 11, 2019 |  BC Week In Review  |  Clinical News

Axsome's AXS-05 meets in Phase II for MDD

Axsome Therapeutics Inc. (NASDAQ:AXSM) added $4.24 (161%) to $6.87 on Jan. 7 after reporting that AXS-05 met the primary endpoint in the Phase II ASCEND trial to treat moderate-to-severe major depressive disorder (MDD). On the...
22:10 , Jan 7, 2019 |  BC Extra  |  Clinical News

Sage rebounds after next-gen postpartum depression readout

Sage Therapeutics Inc. (NASDAQ:SAGE) gained $41.62 (43%) to $139.13 on Monday after it said SAGE-217 met the primary endpoint in the Phase III ROBIN trial to treat women with severe postpartum depression. The move translates...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
04:17 , Dec 8, 2017 |  BC Week In Review  |  Financial News

Axsome raises $9.5M in direct offering

CNS company Axsome Therapeutics Inc. (NASDAQ:AXSM) raised $9.5 million through the sale of 1.8 million units at $5.33 in a registered direct offering led by HC Wainwright. Each unit represents one share of common stock...
19:50 , Aug 4, 2017 |  BC Week In Review  |  Clinical News

Axsome starts Ph III of AXS-05 to treat agitation in AD patients

Axsome Therapeutics Inc. (NASDAQ:AXSM) began the Phase II/III ADVANCE-1 trial of AXS-05 to treat agitation in patients with Alzheimer's disease. The double-blind, U.S. trial will enroll about 435 patients to receive placebo, bupropion or oral...
07:00 , Mar 28, 2016 |  BC Week In Review  |  Clinical News

AXS-05: Phase III started

Axsome began the double-blind Phase III STRIDE-1 trial to compare oral AXS-05 vs. bupropion in about 300 MDD patients who failed 1-2 antidepressant treatments. Patients will receive bupropion for 6 weeks in an open-label, lead-in...